Despite attempts to solve problems with shortages of brand-name medicines in the UK, the issue is far from beings resolved. The latest news is that the UK’s wholesalers have called for a ‘third-party monitoring and survey service’ to help tackle medicines shortages, while the Association of the British Pharmaceutical Industry (ABPI) is calling for sanctions on pharmacists that act as wholesalers.
Drug shortage woes continue in the UK
Home/Pharma News | Posted 27/01/2012 0 Post your comment
The British Association of Pharmaceutical Wholesalers (BAPW) has called on pharmacists and manufacturers to support objective monitoring and reporting of brand-name medicine supplies. The association stressed that the introduction of a third-party monitoring and survey service of medicine supplies to pharmacies and dispensing doctors needed ‘urgent consideration’.
The BAPW adds that although the various stakeholders are working together more closely, ‘inefficiencies remain in the supply chain’, which the BAPW feels could be rebalanced by ‘regulatory enforcement’ and ‘adjustment’.
Meanwhile, the ABPI are calling for the legal separation of pharmacies’ wholesaling and dispensing activities to ensure patients ‘get priority’ when medicines are in short supply according to Chemist+Druggist. The ABPI believe that separating the activities would ensure pharmacists put patients before business.
Currently in the UK there are 1,800 wholesaler licences, which enable pharmacists to export medicines for profit, possibly exacerbating drug shortages. The UK medicines authority–Medicines and Healthcare products Regulatory Agency–has already stated that pharmacists with ‘unusual purchasing patterns’ could face investigation over their exporting businesses.
The views of the APBI and BAPW are expected to be presented at the first oral evidence session of the All-Party Pharmacy Group’s (APPG’s) Inquiry into medicine shortages, which was scheduled at the House of Commons on 24 January 2012.
Related articles
UK drug shortages are far from being solved
UK drug shortages continue to affect pharmacists and patients
Source: BAPW, Chemist+Druggist
Guidelines
Regulatory update for post-registration of biological products in Brazil
New regulations in Brazil for the registration of biosimilars
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Meitheal expands portfolio with three biosimilars through exclusive US licensing agreement
EMS proposes merger with Hypera to form Brazil's largest drugmaker
Bio-Thera and Gedeon Richter partner to commercialize Stelara biosimilar BAT2206
Advances for Biocon Biologics’ Stelara and Eylea biosimilars
Comments (0)
Post your comment